惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

B
Blog RSS Feed
量子位
Y
Y Combinator Blog
大猫的无限游戏
大猫的无限游戏
B
Blog
U
Unit 42
C
Check Point Blog
I
InfoQ
aimingoo的专栏
aimingoo的专栏
雷峰网
雷峰网
OSCHINA 社区最新新闻
OSCHINA 社区最新新闻
博客园 - 【当耐特】
人人都是产品经理
人人都是产品经理
The Cloudflare Blog
H
Help Net Security
MongoDB | Blog
MongoDB | Blog
博客园 - Franky
H
Hackread – Cybersecurity News, Data Breaches, AI and More
J
Java Code Geeks
Microsoft Azure Blog
Microsoft Azure Blog
让小产品的独立变现更简单 - ezindie.com
让小产品的独立变现更简单 - ezindie.com
云风的 BLOG
云风的 BLOG
宝玉的分享
宝玉的分享
爱范儿
爱范儿

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call ...
2026-05-14 · via All Articles on Seeking Alpha

Q1: 2026-05-13 Earnings Summary

EPS of -$0.18 beats by $0.00

 | 

Revenue of

$0.00

misses by $1,820.00

Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call May 13, 2026 5:00 PM EDT

Company Participants

Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer
David Chang - Co-Founder, President, CEO & Director
Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer
Geoffrey Parker - Executive VP & CFO

Conference Call Participants

Michael Yee - UBS Investment Bank, Research Division
Tyler Van Buren - TD Cowen, Research Division
Biren Amin - Piper Sandler & Co., Research Division
Salveen Richter - Goldman Sachs Group, Inc., Research Division
Samantha Semenkow - Citigroup Inc., Research Division
Matthew Phipps - William Blair & Company L.L.C., Research Division
Jack Allen - Robert W. Baird & Co. Incorporated, Research Division
John Newman - Canaccord Genuity Corp., Research Division
Reni Benjamin - Citizens JMP Securities, LLC, Research Division
Lut Ming Cheng - JPMorgan Chase & Co, Research Division

Presentation

Operator

Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter 2026 Conference Call. [Operator Instructions] Please be aware that today's conference call is being recorded.

I would now like to turn the call over to Christine Cassiano, Chief Corporate Affairs and Brand Strategy Officer.

Ms. Cassiano, please go ahead.

Christine Cassiano
Executive VP, Chief Corporate Affairs & Brand Strategy Officer

Thank you, operator, and welcome, everyone, to Allogene's conference call. After the market closed, Allogene issued a press release that provided a business update and financial results for the first quarter of 2026. This press release and today's webcast are available on our website.

Following our prepared remarks, we will host a Q&A session and we will aim to keep the call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.